menu
    • menu
    [{"orgOrder":0,"company":"Secretome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"STM-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Secretome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Secretome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Secretome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Secretome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"STM-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Secretome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Secretome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Secretome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Secretome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"STM-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Secretome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Secretome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Secretome Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Secretome Therapeutics

    Menu

    Secretome Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Secretome Therapeutics

    U.S.A arrow
    Cophex
    Not Confirmed

    Secretome Therapeutics

    U.S.A arrow
    Cophex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : STM-01

    Therapeutic Area : Cardiology/Vascular Diseases

    Study Phase : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Secretome Doses First Patient in Phase 1 STM-01 Heart Failure Study

    Details : STM-01 is an investigational, allogeneic neonatal cardiac progenitor cell (nCPC) therapy to improve cardiac function in patients with HFpEF and other inflammatory-driven cardiovascular diseases.

    Product Name : STM-01

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    March 25, 2025

    Lead Product(s) : STM-01

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Secretome Therapeutics

    U.S.A arrow
    Cophex
    Not Confirmed

    Secretome Therapeutics

    U.S.A arrow
    Cophex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : STM-01

    Therapeutic Area : Cardiology/Vascular Diseases

    Study Phase : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Secretome’s STM-01 gets FDA Fast Track for HFpEF Neonatal Cell Therapy

    Details : STM-01 is an investigational, allogeneic neonatal cardiac progenitor cell (nCPC) therapy to improve cardiac function in patients with HFpEF and other inflammatory-driven cardiovascular diseases.

    Product Name : STM-01

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    March 20, 2025

    Lead Product(s) : STM-01

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Secretome Therapeutics

    U.S.A arrow
    Cophex
    Not Confirmed

    Secretome Therapeutics

    U.S.A arrow
    Cophex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : STM-01

    Therapeutic Area : Cardiology/Vascular Diseases

    Study Phase : Phase I

    Sponsor : Undisclosed

    Deal Size : $20.4 million

    Deal Type : Financing

    DEALS_DEV arrow-down

    Secretome Raises $20.4M to Develop Therapies for Cardiomyopathy and Heart Failure

    Details : The funding will enable Secretome to initiate clinical trials for its lead asset, STM-01 for the treatment of heart failure with preserved ejection fraction.

    Product Name : STM-01

    Product Type : Cell and Gene therapy

    Upfront Cash : Undisclosed

    November 25, 2024

    Lead Product(s) : STM-01

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase I

    Sponsor : Undisclosed

    Deal Size : $20.4 million

    Deal Type : Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth